Key facts
- neuroClues’s last known valuation is $13.0M (Apr 2024).
- It has raised $22.4M; the latest was Equity Crowdfunding ($450K) in Jan 2026.
- Notable investors include European Innovation Council, Wing Venture Capital, European Innovation Council (Belgium), Fiona Monceau, François-Xavier De Mevius — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for neuroClues
- ·The full record, as it builds
Funding rounds
No funding rounds for neuroClues are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About neuroClues
Operator of a MedTech company aiming to become the brain's stethoscope while revolutionizing the early diagnosis of neurological disorders such as Parkinson's and Alzheimer's. The company offers AI-driven eye-tracking technology that enables clinicians to detect brain health issues earlier, improving patient outcomes and treatment strategies.
- Sector
- Healthcare
- HQ
- Louvain-la-Neuve, Belgium
- Founded
- 2020
- Employees
- 29
- Website
- neuroclues.com/
- Ownership
- Privately Held (backing)
neuroClues doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in neuroClues shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on neuroClues in its N-PORT filings yet. We sweep new filings monthly.